PA-BENTLEY-SYSTEMS
24.3.2021 15:03:10 CET | Business Wire | Press release
Bentley Systems, Incorporated, (Nasdaq: BSY), the infrastructure engineering software company, has announced its call for nominations for the 2021 Going Digital Awards in Infrastructure program. Formerly known as the Year in Infrastructure Awards, this global awards program, judged by independent juries of industry experts, recognize infrastructure projects for digital innovations that improve project delivery and/or asset performance. The deadline for nominations is May 21, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005135/en/
The Going Digital Awards are an integral part of Bentley’s annual Year in Infrastructure Conference. The conference brings together infrastructure professionals and industry thought leaders from around the world to share best practices and learn about the latest advances in technology that will improve infrastructure project delivery and asset performance. Winners will be announced during the awards ceremony at the culmination of the conference.
Users of Bentley software are invited to nominate their projects in the Going Digital Awards program, no matter which phase the project is in – planning/conception, design, construction, or operations. The three finalists chosen for each awards category will get a global platform to present their projects before the judges, industry thought leaders, and media members.
Every project nominated for an award receives recognition across the global infrastructure community. Through the Going Digital Awards program, participants:
- Gain global recognition by having their infrastructure projects profiled in Bentley’s Infrastructure Yearbook , which is distributed to media, government, and industry influencers around the world. All winning and finalist projects are also featured on bentley.com .
- Enhance their competitive edge by demonstrating to existing and potential clients the value the participants add to projects through their digital innovations.
- Receive coverage from global media and support from the Bentley team in marketing and promoting their respective projects to the media.
The 2021 Going Digital Awards will recognize outstanding achievements for infrastructure projects and assets in the following categories:
- Bridges
- Buildings and Campuses
- Digital Cities
- Digital Construction
- Geotechnical Engineering
- Land and Site Development
- Manufacturing
- Mining and Offshore Engineering
- Power Generation
- Project Delivery Information Management
- Rail and Transit
- Reality Modeling
- Roads and Highways
- Road and Rail Asset Performance
- Structural Engineering
- Utilities and Communications
- Utilities and Industrial Asset Performance
- Water and Wastewater Treatment Plants
- Water, Wastewater and Stormwater Networks
Additionally, projects that represent Bentley’s mission of advancing infrastructure but transcend the narrower focus of the individual category awards can be considered for Founders’ Awards (formerly known as the Special Recognition Awards) including, but not limited to:
- Advancements in Digital Twins for Project Delivery (Project Digital Twins) for a project using a digital twin to gain useful insights, such as understanding the impact of change and design alternatives or highlighting issues with the quality of project data, to collaborate with the extended project team more effectively or to model the performance of a project and its construction.
- Advancements in Digital Twins for Asset Performance (Performance Digital Twins) for a project involving an operating infrastructure asset that uses a digital twin to gain useful insights to improve the performance in areas such as throughput, safety, compliance, or maintenance, to evaluate the relative impact of different operational strategies, to support training operational staff, or to support remote operations.
- Advancements in Sustainability and Resilience for a project that has leveraged digital technology in the design or operations of an infrastructure asset to achieve better sustainability (lower carbon footprint, better use of renewables, reduced environmental impact), higher resilience (ability to withstand and recover from human-made or natural disasters, adaptability to changing conditions), or to deliver social benefits (includes health and safety and community benefit) or improved governance (facilitates and promotes transparency in reporting, compliance, codes of conduct, and risk management).
For additional information about the 2021 Going Digital Awards program, or to nominate a project, visit the Going Digital Awards in Infrastructure website.
Watch a one-minute video about the nomination process.
Image: Going Digital Awards in Infrastructure logo
Image courtesy of Bentley Systems
Caption: Participate in the 2021 Going Digital Awards to gain global recognition for digital advancements in infrastructure.
About Bentley Systems’ Year in Infrastructure Conference
The Year in Infrastructure Conference is a global gathering of leading executives in the world of infrastructure design, construction, and operations focused on best practices and technologies for going digital. The conference is globally recognized as the leading forum for addressing the current priorities and opportunities that impact the infrastructure industry. Attendees hear from industry thought leaders, engage in forums and discussions, and learn about technologies and best practices that will shape the future of infrastructure delivery and operations.
About Bentley Systems
Bentley Systems (Nasdaq: BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, and industrial facilities. Our offerings include MicroStation -based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,000 colleagues and generates annualized revenues of more than $800 million in 172 countries. www.bentley.com
# #
© 2021 Bentley, the Bentley logo, AssetWise, iTwin, MicroStation, and ProjectWise are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005135/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
